iPharma
What's next for digital in pharma?
PharmaTimes -
April 2018
It’s all about digital in this issue of PharmaTimes.
In our cover feature (p29) we’ll be taking a look at all the ways digital tech will be changing the industry in years to come. We also have features taking a deeper look at how sensor technology is being embedded in pills to measure adherence (p26) and how AI is being used to tackle non-alcoholic fatty liver disease (p33).
You can also look forward to a big focus on AI in our next issue, where we’ll be looking at how it’s impacting every aspect of pharma.
Elsewhere we take a look at several important IP cases that might change the industry (p22), shake-ups in medical device regulation (p20) and how biotech Probiodrug is hoping to take on the notoriously difficult disease area of Alzheimer’s (p36).
Don’t forget that tickets are now on sale for our International Clinical Researcher of the Year Competition – and on p38 we reveal the finalists who will be competing for these prestigious awards.
I hope you enjoy the issue.
April 2018 - magazine highlights
Taking Alzheimer's head-on
German biotech Probiodrug is hoping its lead candidate can make a difference in this notoriously tough disease area. We asked CEO Konrad Glund what the future might hold for Alzheimer’s treatment
Company focus: Perspectum Diagnostics
How this Oxford spinout is using AI to tackle challenges in non-alcoholic fatty liver disease
The new power brokers
How pharma should adapt to changes in the NHS that are impacting decision-making in primary care
A new landscape for medical devices
Pharma businesses need to prepare now for the EU’s sweeping regulatory changes to devices and in vitro diagnostics
Patent pending
A look at some of the most important pharma IP cases from the past year and the rest of 2018
Living in interesting times
For investors the future is bright, but it isn’t pharma
Digital sensor medicines: the holy grail in adherence?
Will drugs that track adherence when ingested be a tough pill for patients to swallow?
SmartPeople: Mark Samuels
The industry veteran talks about how he’s helping to change drug discovery as chief business and strategy officer of the new Medicines Discovery Catapult
Patient Files: Niemann-Pick type C
After having two of their children diagnosed with NP-C, Phil and Andrea Marella set up a charity to help find a cure for this devastating neurodegenerative disease
